5055 Small-conductance potassium channel
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Benzenoids | 2 | 0.1 | 14× | not tested | |
| Organoheterocyclic compounds | 2 | 0.3 | 6.59× | not tested | |
| Organic acids and derivatives | 2 | 0.3 | 6.55× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00740 | 657 | Riluzole | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| PHU | 1-phenylurea | 3 |
| 1KP | (3E)-6,7-dichloro-3-(hydroxyimino)-1,3-dihydro-2H-indol-2-one | 2 |
| 0W8 | 1-ethyl-1,3-dihydro-2H-benzimidazol-2-one | 1 |
| 657 | 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine | 1 |
| 658 | N-(4-chlorophenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-amine | 1 |
| AJV | 7-fluoro-3-(hydroxyamino)-2H-indol-2-one | 1 |
| AJY | (3Z)-6-bromo-3-(hydroxyimino)-5-methyl-1,3-dihydro-2H-indol-2-one | 1 |